Browse the evidence

A total of 107 cases of suicidal and/or self-injurious ADRs were reported with semaglutide.

Awareness of the number of reported cases can inform risk assessments for semaglutide use.

There is a lack of data in female animal models or women regarding GLP-1 research.

More research is needed in female populations to understand GLP-1 effects.

There were no cases of pulmonary aspiration of gastric contents.

While there is an increased risk of residual gastric content, the absence of pulmonary aspiration suggests a level of safety in this context.

Lifestyle interventions were not superior to usual care in reducing cardiovascular mortality (RR 0.99; 95% CI 0.79-1.23).

Practitioners should consider that lifestyle interventions may not significantly impact cardiovascular mortality in this population.

Lifestyle interventions were not superior to usual care in reducing all-cause mortality (RR 0.93; 95% CI 0.85-1.03).

Practitioners should note that lifestyle interventions may not significantly affect all-cause mortality in this population.

Subgroup, sensitivity, and meta-regression analyses showed no influence of various factors on mortality outcomes.

Practitioners should be aware that various factors did not affect the mortality outcomes in this study.

GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration compared to SGLT-2 inhibitor use.

Practitioners can consider GLP-1 receptor agonists safe regarding pulmonary aspiration risk before endoscopy.

No increased risk of pulmonary aspiration was observed among adults with type 2 diabetes using GLP-1 receptor agonists compared to SGLT-2 inhibitors.

This finding may influence preprocedural protocols for endoscopy in patients using GLP-1 receptor agonists.

Tirzepatide and semaglutide are not cost-effective at current net prices, requiring significant discounts to meet cost-effectiveness thresholds.

Healthcare providers should consider the cost-effectiveness of these medications when making treatment decisions.

Cardiovascular disease (CVD) is the leading cause of death and disability worldwide.

Healthcare practitioners should prioritize addressing CVD in their practice.

There is no consensus definition for 'failure' in resistance training literature.

Practitioners should be aware of the lack of standardization in training definitions when interpreting research.

Preoperative use of GLP-1 receptor agonists is not significantly associated with the odds of postoperative aspiration pneumonia.

Clinicians may reconsider the necessity of withholding GLP-1 RAs preoperatively based on these findings.

Patients using GLP-1 receptor agonists are more likely to be female and diagnosed with both obesity and diabetes compared to nonusers.

Understanding the demographics of GLP-1 RA users can inform targeted interventions and education.

Higher sustained pharmacy costs were the main driver of the cost difference favoring MBS over GLP-1 receptor agonists.

Healthcare providers should consider ongoing medication costs when recommending obesity treatments.

Restrictive diets such as very-low-carb, ketogenic, very-low-calorie diets, and intermittent fasting have scarce evidence for direct benefit to NAFLD.

Practitioners should be cautious in recommending restrictive diets for NAFLD due to insufficient evidence of their benefits.

The random forest classification algorithm exhibits superior accuracy rates of 97% for Obesity_Type_I, 99% for Obesity_Type_II, and 83% for Obesity_Type_III compared to alternative classifiers.

Practitioners can utilize machine learning algorithms, particularly random forests, for more accurate obesity classification.

The study demonstrates the efficacy of machine learning methodologies in forecasting different forms of obesity.

Machine learning can be a powerful tool for predicting obesity, aiding in prevention and management strategies.

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

No association was found with other disorders of the optic nerve or visual pathways.

Other optic nerve or visual pathway disorders are not linked to semaglutide or tirzepatide use.